Cutaneous T cell lymphomaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

671 records returned

Immunomodulatory therapy of cutaneous T-cell lymphoma: A multimodality approach in advanced diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dialogues in Dermatology, a monthly audio program from the American Academy of Dermatology, contains discussions between dermatologists on timely topics. Commentaries from Dialogues Editor-in-Chief Jacqueline M. Junkins-Hopkins, MD, are provided after each discussion as a topic summary and are provided here as a special service to readers of the Journal of the American Academy of Dermatology. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - November 19, 2009 Category: Dermatology Authors: Jacqueline M. Junkins-Hopkins Tags: Dialogues in Dermatology Source Type: journals

CorrectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001-17. On page 1002 of the article above, the following statement was incorrect: Patients with mild psoriasis have a relative risk of 1.42 and 3.18 of developing Hodgkin's lymphoma and CTCL, respectively. Patients with severe psoriasis have a relative risk of 4.10 and 10.75 of developing Hodgkin's lymphoma and CTCL, respectively. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - November 19, 2009 Category: Dermatology Tags: Corrections Source Type: journals

Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoidesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF. (Source: Journal of the European Academy of Dermatology and Venereology)
Source: Journal of the European Academy of Dermatology and Venereology - November 19, 2009 Category: Dermatology Authors: P Ponte, V Serrão, M Apetato Source Type: journals

Folliculotropic mycosis fungoides with eosinophilia and CD30+ large-cell transformation: a case with a fatal outcome presenting with multifocal lesions and leonine faciesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case of folliculotropic mycosis fungoides (FMF) presenting with multiple ulcerative nodular lesions and persistent eosinophilia. Severe facial lesions resulted in a leonine appearance. On histopathological examination, nodular infiltration of large CD30+ large cells was seen. When the previous biopsy specimens were reviewed, marked folliculotropism with atypical lymphocytes was identified in previous specimens 20 years before the blastic transformation. CC chemokine receptor 3 was expressed in tumour cells, whereas CXC chemokine receptor 3 was negative. Expression of interleukin (IL)-5 was detected in a few mon...
Source: Clinical And Experimental Dermatology - November 19, 2009 Category: Dermatology Authors: M. Ishibashi, K. Ohshima, K. R. Chen Source Type: journals

Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Acute and chronic graft versus host disease are frequent and potentially severe complications of allogeneic hematopoietic stem cell transplantation and are among the leading causes of non-relapse transplant-related mortality. For patients with steroid refractory disease, prognosis is particularly poor and although a variety of treatment options are available, responses are commonly transient and the side effects often intolerable. Since it was first introduced for the treatment of cutaneous T-cell lymphoma, extracorporeal photo-apheresis has been utilized as an immunomodulatory therapy for certain autoimmune dise...
Source: Transfusion and Apheresis Science - November 18, 2009 Category: Hematology Authors: Kristin Baird, Alan S. Wayne Tags: Guest Editor: Stephen J. Wagner Source Type: journals

Contribution of Dermatologic Surgery in WarEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This report outlines the important contribution of dermatologic surgery in the combat environment. The authors have indicated no significant interest with commercial supporters. (Source: Dermatologic Surgery)
Source: Dermatologic Surgery - November 13, 2009 Category: Dermatology Authors: MAJOR J. SCOTT HENNING, BAHAR F. FIROZ Source Type: journals

FDA Approves New Drug For Rare Cancer Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin) is injectable and is marketed by Gloucester Pharmaceuticals Inc of Cambridge, Massachusetts. Every year, about 1,500 Americans are newly diagnosed with CTCL, a type of non-Hodgkin's lymphoma. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 12, 2009 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news

FDA Approves New Drug For Rare Cancer Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin) is injectable and is marketed by Gloucester Pharmaceuticals Inc of Cambridge, Massachusetts. Every year, about 1,500 Americans are newly diagnosed with CTCL, a type of non-Hodgkin's lymphoma. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 12, 2009 Category: Cancer & Oncology Tags: Regulatory Affairs / Drug Approvals Source Type: news

How I treat mycosis fungoides and Sezary syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a "stage-based" approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy. S...
Source: Blood - November 12, 2009 Category: Hematology Authors: Prince, H. M., Whittaker, S., Hoppe, R. T. Tags: How I Treat, Free Research Articles, Lymphoid Neoplasia Source Type: journals

Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, gene expression profiling is beginning to change the pathological classification, the prognosis profiles and the therapeutic approach in T-cell lymphomas. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 12, 2009 Category: Hematology Authors: Régis Costello, Carole Sanchez, Thérèse Le Treut, Pascal Rihet, Jean Imbert, Gérard Sébahoun Source Type: journals

Immunoelectron microscopy in mycosis fungoides and benign dermatoses. Expression of CD3, CD4 and CD7 receptors.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Mycosis fungoides is an epidermotropic cutaneous T-cell lymphoma (CTCL).Specimens for presented study were taken from sixteen patients with MF confirmed by immunohistochemical methods and PCR and from nine patients with benign dermatoses. To demonstrate CD3, CD4 and CD7 antigens immunogold method was used. We saw morphological differences between lymphocytes from MF and benign dermatoses. In MF, CD3 and CD4 were present rather in form of clusters placed on the surface of cell. On the contrary -CD3 to CD7 distribution analysis showed that these antigens were present rather individually, however there were seen clusters ...
Source: Neoplasma - November 11, 2009 Category: Cancer & Oncology Authors: Grzanka AA, Placek W, Grzanka A, Sokolowska-Wojdylo M, Zuryn A Tags: Neoplasma Source Type: journals

FDA Approves Romidepsin for the Treatment of Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Romidepsin for injection has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least 1 prior systemic therapy. The US Food and Drug Administration granted... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - November 10, 2009 Category: Cancer & Oncology Source Type: news

FDA Approves Drug Treatment For Rare CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). Cutaneous T-cell lymphoma is a slow-growing cancer of infection-fighting white blood cells called T-lymphocytes. Most cases start with dry skin, red rash, and itching that can become severe. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 10, 2009 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

FDA Approves Drug Treatment For Rare CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). Cutaneous T-cell lymphoma is a slow-growing cancer of infection-fighting white blood cells called T-lymphocytes. Most cases start with dry skin, red rash, and itching that can become severe. The skin may develop tumors that can become ulcerated, causing infection. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 10, 2009 Category: Cancer & Oncology Tags: Cancer / Oncology Source Type: news

Istodax Approved for Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Modern Medicine)
Source: Modern Medicine - November 10, 2009 Category: Journals (General) Source Type: info

TCRgamma gene rearrangement in cutaneous T-cell lymphoma: comparative study of PCR with denaturing gradient gel electrophoresis and GeneScan analysis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions BIOMED-2-GS analysis of the TCRgamma gene is as sensitive and specific as DGGE for CTCL diagnosis. In addition, BIOMED-2-GS is less time-consuming and gives more information concerning the size and nature of TCR-GR. PMID: 19906072 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - November 10, 2009 Category: Dermatology Authors: Goeldel AL, Cornillet-Lefebvre P, Durlach A, Birembaut P, Bernard P, Nguyen P, Grange F Tags: Br J Dermatol Source Type: journals

FDA Approves Drug Treatment for Rare CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cutaneous T-cell lymphoma affects about 1,500 Americans annually The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 9, 2009 Category: American Health Source Type: organizations

Istodax Approved for Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Istodax Approved for Cutaneous T-Cell LymphomaCategory: Health NewsCreated: 11/6/2009 4:10:00 PMLast Editorial Review: 11/9/2009 (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 9, 2009 Category: Cancer & Oncology Source Type: consumer

Extragenital lichen sclerosus et atrophicus mimicking cutaneous T-cell lymphoma: report of a caseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case of extragenital LSA in which both histological patterns were present in the same clinically homogenous and stable lesion. A 27-year-old man presented with a history of white atrophic plaques on the trunk. A biopsy of an abdominal lesion revealed epidermal thinning, a superficial perivascular lymphoid cell infiltrate with focal epidermotropism, mild nuclear atypia and perinuclear halos. Immunophenotyping showed decreased CD5 and CD7, with a slight predominance of CD8-positive T-lymphocytes. All these changes were suggestive of MF. However, a repeat biopsy 3 months later from the same stable plaque revealed ...
Source: Journal of Cutaneous Pathology - November 9, 2009 Category: Pathology Authors: Ravi Suchak, Roberto Verdolini, Alistair Robson, Catherine M. Stefanato Source Type: journals

FDA approves romidepsin (Istodax®) for treatment of cutaneous T-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BioSpace Area: News The FDA has approved romidepsin (Istodax®), a histone deacetylase (HDAC) inhibitor, for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. CTCL is a type of non-Hodgkin's lymphoma, but caused by a mutation of T cells, unlike most non-Hodgkin's lymphomas which are generally of B-cell origin. Approval was based upon two prospective multicentre, single-arm clinical studies in 167 patients, which reported overall objective disease response rates (primary efficacy endpoint) of 34% and 35%. The most common adverse reactions reported i...
Source: NeLM - Oncology - November 9, 2009 Category: Cancer & Oncology Source Type: organizations

Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplantEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: British Journal of Dermatology)
Source: British Journal of Dermatology - November 9, 2009 Category: Dermatology Authors: S. Okada, Y. Nannya, S. Ota, Y. Takazawa, G. Yamamoto, K. Kumano, K. Izutsu, T. Takahashi, S. Chiba, M. Kurokawa Source Type: journals

Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19903173 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - November 9, 2009 Category: Dermatology Authors: Okada S, Nannya Y, Ota S, Takazawa Y, Yamamoto G, Kumano K, Izutsu K, Takahashi T, Chiba S, Kurokawa M Tags: Br J Dermatol Source Type: journals

FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 7, 2009 Category: Consumer Health News Tags: lymphoma / Leukemia / Myeloma Source Type: news

FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 7, 2009 Category: Cancer & Oncology Tags: lymphoma / Leukemia / Myeloma Source Type: news

Histone Deacetylase Inhibitors in Cancer Therapy [REVIEW ARTICLE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Lane, Chabner Tags: Phase I and Clinical Pharmacology REVIEW ARTICLE Source Type: journals

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Piekarz, Frye, Turner, Wright, Allen, Kirschbaum, Zain, Prince, Leonard, Geskin, Reeder, Joske, Figg, Gardner, Steinberg, Jaffe, Stetler-Stevenson, Lade, Fojo, Bates Tags: Chemotherapy Hematologic Malignancies Source Type: journals

FDA Approves Romidepsin for Refractory Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved the HDAC inhibitor romidepsin for the treatment of cutaneous T-cell lymphoma in patients who have received at least 1 prior systemic therapy. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2009 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Istodax Approved for Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
It's a disfiguring cancer affecting the skin (Source: Forbes.com Health News)
Source: Forbes.com Health News - November 6, 2009 Category: Consumer Health News Source Type: news

FDA Okays New Treatment for T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
WASHINGTON (MedPage Today) -- The FDA has approved romidepsin (Istodax) for patients with cutaneous T-cell lymphoma who have received at least one prior systemic therapy. (Source: MedPage Today Product Alert)
Source: MedPage Today Product Alert - November 6, 2009 Category: Drugs & Pharmacology Source Type: news

FDA Approves Gloucester Pharmaceuticals' Istodax for Patients with Cutaneous T-cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 5, 2009 - Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved Istodax (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 6, 2009 Category: Drugs & Pharmacology Source Type: news

FDA approves romidepsin for cutaneous T-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: HemOncToday.com)
Source: HemOncToday.com - November 6, 2009 Category: Cancer & Oncology Source Type: info

In Mycosis Fungoides, Immunophenotypes May Vary Between Skin and BloodEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
T-cell immunophenotype of mycosis fungoides involving the skin varies from that involving the blood in more than half the cases of this cutaneous T-cell lymphoma. Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 4, 2009 Category: Internal Medicine Tags: Pathology & Lab Medicine Source Type: info

Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Immunodeficiency-related lymphoproliferative disorders (IR-LPD) may occur in the setting of immunosuppressive therapy with methotrexate and TNF-[alpha] antagonists. As far as we are aware, this is the first report of an Epstein-Barr virus-associated B-cell lymphoproliferative disorder, secondary to methotrexate therapy in a patient with mycosis fungoides/Sézary syndrome. Curry JL, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome. (Source: Journal of Cutaneous Pathology)
Source: Journal of Cutaneous Pathology - November 4, 2009 Category: Pathology Authors: Jonathan L. Curry, Victor G. Prieto, Dan M. Jones, Franscisco Vega, Madeleine Duvic, A. Hafeez Diwan Source Type: journals

[Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the case of a young man still in complete remission for transformed mycosis fungoides 14 years after autologous stem cell transplantation. CASE REPORT: A 25-year-old man presenting eczema-like patches since childhood was treated by chemotherapy for multiple lymphadenopathies considered as Hodgkin's lymphoma. He was referred with diffuse skin tumours and infiltrated patches. Histology of tumour samples revealed atypical T-cell infiltrate with epidermotropism and presence of more than 25% of large CD30-positive cells. Non-infiltrated patches showed small T-cell lymphoma with epidermotropism. Histological verificati...
Source: Annales de Dermatologie et de Cenereologie - November 1, 2009 Category: Dermatology Authors: Di Lucca-Chrisment J, Maubec E, Grossin M, Marinho E, Varet B, Maillard H, Crickx B Tags: Ann Dermatol Venereol Source Type: journals

Identification of Key Regions and Genes Important in the Pathogenesis of Sezary Syndrome by Combining Genomic and Expression MicroarraysEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we used single nucleotide polymorphism and comparative genomic hybridization array to study DNA copy number changes and loss of heterozygosity for 28 patients affected by Sézary syndrome (SS), a rare form of cutaneous T-cell lymphoma (CTCL). Our data identified, further confirming previous studies, recurrent losses of 17p13.2-p11.2 and 10p12.1-q26.3 occurring in 71% and 68% of cases, respectively; common gains were detected for 17p11.2-q25.3 (64%) and chromosome 8/8q (50%). Moreover, we identified novel genomic lesions recurring in >30% of tumors: loss of 9q13-q21.33 and gain of 10p15.3-10p12.2. In...
Source: Cancer Research - October 29, 2009 Category: Cancer & Oncology Authors: Caprini, E., Cristofoletti, C., Arcelli, D., Fadda, P., Citterich, M. H., Sampogna, F., Magrelli, A., Censi, F., Torreri, P., Frontani, M., Scala, E., Picchio, M. C., Temperani, P., Monopoli, A., Lombardo, G. A., Taruscio, D., Narducci, M. G., Russo, G. Tags: Molecular Biology, Pathobiology, and Genetics Source Type: journals

A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis VulgarisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Rep Dermatol 2009;1:60-65 (DOI:10.1159/000249148) (Source: Karger Publishers)
Source: Karger Publishers - October 26, 2009 Category: Cancer & Oncology Source Type: journals

Serum interleukin-27 levels in patients with cutaneous T-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Clinical And Experimental Dermatology)
Source: Clinical And Experimental Dermatology - October 22, 2009 Category: Dermatology Authors: T. Miyagaki, M. Sugaya, S. Shibata, H. Ohmatsu, H. Fujita, K. Tamaki Source Type: journals

Current and Emerging Treatment Options in Cutaneous T-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Expert Recap - John A. Zic, MD, discusses the pathogenesis, staging, and treatment options for patients with cutaneous T-cell lymphoma. (Source: Clinical Care Options Oncology - Lung Cancer)
Source: Clinical Care Options Oncology - Lung Cancer - October 21, 2009 Category: Cancer & Oncology Source Type: journals

Current and Emerging Treatment Options in Cutaneous T-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Downloadable slideset on the standards of care and emerging novel therapies for the treatment of cutaneous T-cell lymphoma. (Source: Clinical Care Options Oncology - Lymphoma)
Source: Clinical Care Options Oncology - Lymphoma - October 21, 2009 Category: Cancer & Oncology Source Type: journals

About the cutaneous targets of bexarotene in CTCL patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Please cite this paper as: About the cutaneous targets of bexarotene in CTCL patients. Experimental Dermatology 2009.Abstract: There are several approved therapies for cutaneous T-cell lymphoma (CTCL). The retinoids are one of the major biologic response modifiers used in CTCL, producing good response rates but few complete responses. Bexarotene has been demonstrated to act on malignant T-cells by inducing their apoptosis, but nothing is known about its role on keratinocytes and Langerhans cells. Immunohistochemical analysis using CD1a, HLA-DR, ICAM-1 (activation markers), CD95 and CD40 (apoptosis markers) was conducted on...
Source: Experimental Dermatology - October 20, 2009 Category: Dermatology Authors: Anne Chantal Knol, Gaëlle Quéreux, Anabelle Brocard, Fabienne Ballanger, Amir Khammari, Jean-Michel Nguyen, Brigitte Dréno Source Type: journals

Absence of modulation of CD4+CD25high regulatory T cells in CTCL patients treated with bexaroteneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Please cite this paper as: Absence of modulation of CD4+CD25high regulatory T cells in CTCL patients treated with bexarotene. Experimental Dermatology 2009.Abstract: Cutaneous T-cell lymphoma (CTCL) are a heterogeneous group of lymphoproliferative disorders, characterized by the infiltration of the epidermis by mature and activated malignant CD4+ T-lymphocytes. Retinoids such as retinoic acid and synthetic analogues have long been used alone or in combination with other therapies for CTCL. Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refract...
Source: Experimental Dermatology - October 20, 2009 Category: Dermatology Authors: Anne Chantal Knol, Gaëlle Quéreux, Anabelle Brocard, Fabienne Ballanger, Amir Khammari, Jean-Michel Nguyen, Brigitte Dréno Source Type: journals

Mycosis fungoides presenting as a pustular eruptionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A 78-year-old woman presented with a generalized and figurate erythema with marginal lamellar scaling and pustulation. In addition, scaly, erythematous, and atrophic plaques with occasional pustules were found on the trunk, arms and legs (). Several skin biopsy specimens showed two distinct phenomena: a) a sub- and intracorneal pustule and b) a bandlike lymphocytic infiltrate of atypical lymphocytes with cerebriform nuclei. The atypical lymphocytes showed extensive epidermotropism and intraepidermal abscess formation (). Immunohistochemically the atypical lymphocytes were CD45-R0+, CD3+, CD4+ and CD8+ cells. Molecular biol...
Source: Journal of the American Academy of Dermatology - October 17, 2009 Category: Dermatology Authors: Heike Pabsch, Johannes Kunze, Jörg Schaller Tags: Case Letters Source Type: journals

Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A 56-year-old male patient had a history of mantle-cell lymphoma, which was treated with polychemotherapy and reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation (ASCT) from his healthy sister with an identical human leucocyte antigen profile. Six years after transplantation, the patient developed asymptomatic eczema-like cutaneous lesions. Histologically the lesions contained a dense superficial lichenoid infiltrate, mainly consisting of CD4+ atypical medium to large lymphocytes showing indented hyperchromatic nuclei. In situ hybridization for Epstein[ndash]Barr virus was negative. PCR ampli...
Source: Clinical And Experimental Dermatology - October 9, 2009 Category: Dermatology Authors: A. Santos-Briz, A. Romo, P. Antúnez, C. Román, M. Alcoceba, J. L. Garcia, L. Vazquez, M. González, P. Unamuno Source Type: journals

Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report 3 patients whose tumor-stage mycosis fungoides was not sufficiently controlled by several preceding systemic therapies, including liposome-encapsulated doxorubicin. All patients experienced excellent improvement with 250 mg/m2 gemcitabine weekly, a low-dose regimen that is predicted to be less toxic compared with standard-dose gemcitabine. PMID: 19858049 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 1, 2009 Category: Cancer & Oncology Authors: Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, Schön MP, Kretschmer L Tags: Clin lymphoma Myeloma Source Type: journals

Panel Backs Romidepsin as Second-Line CTCL TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SILVER SPRING, MD. — The Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10-0, with 1 abstention, that two single-arm trials of romidepsin show that the drug has a favorable risk-benefit profile as a second-line treatment for patients with cutaneous T-cell lymphoma. (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 30, 2009 Category: Dermatology Authors: ELIZABETH MECHCATIE Tags: News From the FDA Source Type: journals

Antibody-based therapy of leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Review ArticlesJohn C. Morris, Thomas A. Waldmann, Expert Reviews in Molecular Medicine, Volume 11 , pp e29AbstractOver the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also activ...
Source: Expert Reviews in Molecular Medicine - September 30, 2009 Category: Molecular Biology Source Type: journals

Etanercept/infliximab: Cutaneous T cell lymphoma: 2 case reportsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - September 30, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

An outbreak of furniture related dermatitis ('sofa dermatitis') in Finland and the UK: history and clinical casesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In February 2007, an epidemic of severe dermatitis from Chinese recliner chairs and sofas started to unfold first in Finland and a few months later in the UK. Some patients reacted in patch tests (PTs) strongly to the material of their furniture, either leather or fabric. There have been hundreds of reports of chair or sofa dermatitis from Finland and the UK, with all cases linked to the same furniture factory in China. Clinical findings in both countries were very similar and unlike any known dermatosis. Many cases have been quite severe, resembling mycosis fungoides or septic infections, requiring hospitalization. Commer...
Source: Journal of the European Academy of Dermatology and Venereology - September 29, 2009 Category: Dermatology Authors: P Susitaival, SM Winhoven, J Williams, K Lammintausta, T Hasan, MH Beck, B Gruvberger, E Zimerson, M Bruze Source Type: journals

Drug That Crosses Blood-Brain Barrier Reduces Formation of Brain Metastases in MiceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug vorinostat is able to cross the blood-brain barrier and reduce the development of large metastatic tumors in mice brains by 62 percent when compared to mice that did not receive the drug, according to a new study. In humans, the drug has been approved by the U.S. Food and Drug Administration for the treatment of a cancer called cutaneous T-cell lymphoma but can be used experimentally to study its effectiveness against other cancers. This research, by investigators at the National Cancer Institute (NCI), part of the National Institutes of Health, and their col...
Source: National Institutes of Health (NIH) News Releases - September 29, 2009 Category: American Health Source Type: news

Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sézary syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: British Journal of Dermatology)
Source: British Journal of Dermatology - September 28, 2009 Category: Dermatology Authors: S. Molin, T. Ruzicka Source Type: journals